Recepción del artículo: 19 de Enero, 2006

Aprobación: 27 de Diciembre, 2004

Primera edición: 5 de Marzo, 2007

Palabras clave

Clasificación en siicsalud
Artículos originales> Expertos de Iberoamérica>
página www.siicsalud.com/des/des044/05809002.htm

Especialidades
Principal: Neurología
Relacionadas: Farmacología,  Medicina Farmacéutica,  Medicina Interna

Enviar correspondencia a:
Dra. Mónica Adriana Diez. Consultorio de Cefaleas Hospital Zubizarreta. Av. Nueva York 3952, Capital Federal, Argentina.

Patrocinio y reconocimiento
Agradecimientos: Al Dr. Barrientos Uribe Nelson y todo el equipo del Hospital, DIPRECA, por el entrenamiento en el uso de la toxina botulínica en cefaleas; al Dr. Jorge Leston por su aporte académico permanente; al Dr. Ricardo Allegri, Jefe del Servicio de Neurología, Hospital Zubizarreta.

Bibliografía del artículo

1. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8:19-28.
2. Menken M, Munsat TL, Toole JF. The global burden of diseases study: Implications for neurology, Arch Neurol 2000; 57(3):418-420.
3. Rasmussen B. Epidemiology of Headache. Cephalagia 1995; 15:45-48.
4. Rasmussen B. Epidemiology of Headache. Cephalalgia 2001; 21:774-777.
5. Ramadan NM, Silberstein SD, Freitag FG, Gilbert TT, Frishberg BM. Evidence based guidelines for migraine headache in the primary care setting. April 2000. Available at : http://www.aan.com/professionals/practice/gui_dis.cfmheadache.
6. Rosales R, Arimura K, Takenaga S, Osame M. Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve1996; 19:488-495.
7. Aoki KR. Pharmacology and immunology of botulinum toxin serotype. J Neurol 2001; 248 (suppl 1):3-10.
8. Borodic G y col. Botulinum toxin therpy for pain and inflammatory disorders.Expert Opinion Invest.Drugs, 2001 10-(8):1531-1544.
9. Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychtry 2004;75:951-957.
10. Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve 1997; 20 (suppl 6) S146-S168.
11. Aoki KR. Basic aspects of botulinum toxin: physiology and pharmacology of therapeutic botulinum neurotoxins. Curr Probl Dermat 2002; 30:107-116.
12. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, BajwaZH. An association between migraine and cutaneous allodynia. Ann Neurol.2000;47:614-624.
13. Diez MA, Leston J, Chaná P, Barrientos N. Toxina botulínica en el tratamiento preventivo de la migraña. Revista Neurológica Argentina.2003.28:205-208
14. Binder WJ, Brinn MF, Blitzer A, Schoenrock Pogoda JM. TB for the treatment of migraine headaches: an open label study. Otolaryngol Head Neck surg 2000; 123:669-676.
15. Mauskop A, Basedo R. Botulinum toxin A is an effective therapy for migraines (abst). Cephalalgia 2000; 20:422.
16. Mauskop A. Long term use of botulinum toxin in migraine headaches. Current pain Headache Rep. 2002; 6:320-323.
17. Miller T, Denny L. Retrospective cohort analysis of 48 chronic headache patients treated with botulinum toxin type A in combination fixed-injection and 2 follow the pain protocol. Presented at: American Headache Society 44^th Annual Scientific Meeting: june 21-23. 2002. Seattle (USA) (abs s138).
18. Blumenfeld A. Botulinum toxin type A as an effective treatment in headache. Presented at 6 the Congress off the European Headache Federation: June 26-30 2002. Turkey. (Abst 81).
19. Mathew NT, Kallasam J, Kaupp A, Meadors L. “Disease modification” in chronic migraine with botulinum toxin type A: long-term experience. Presented at: American Headache Society 44^th Annual Scientific Meeting: june 21-23. 2002. Seattle. Wash. (Abs S107).
20. Smuts JA, Barnard PW. Botulinum toxin type A in the treatment of headache syndromes: a clinical report 79 patients (abst). Cephalalgia 2000; 20:332.
21. Eross EG, Dodick DW. The effects of botulinum toxin type A on disability in
22. Barrientos-Chana.Efficacy and safety of botulinum toxin in the prophylactic treatment of migraine. Presented at: American AcademySociety 44^th june 21-23 2002. Seattle. USA. Abst s108.
23. Silberstein S y col. Botulinum toxin as preventive treatment. Headache 2000, 40:445-450.
24. Brin MF y col. Toxin botulinum in migraine (Abs.) Cephalalgia 2000, 20:386-387.
25. Ondo y col. Botulinum toxin a for the chronic daily headache. Presented at: American Headache Society 44^th June 21-23. Seattle. USA (Abst s 131).
26. Gobel y col. Evidence based medicine: botulinum toxin A in migraine and tension type headache. J Neurol. 2001, Suppl 19:34-38.
27. Gobel y col. Tratment of cronic tension type hedache with botulinum toxin. Cephalalgia 1999, 19:455.
28. Porta M y col. A comparative trial of botulinum toxin A and methilprednisolone for treatment of tension type headache. Curr Rev Pain 4:31-35.
29. Relja y col. Treatment of tension type headache with botulinum toxin. 1 year follow-up. Cephalalgia 2000, 20:336.
30. Schulte M y col. Treatment of tension type headache with botulinum toxin: A pilot study. Europ J Med Res 4:183-186.
31. Smuts y col. Botulinum toxin in the treatment of headache syndromes: a clinical report 79 patiens. Cephalalgia 2000, 20:332.
32. Rollnik J y col. Treatment of tension type headache with boulinum toxin type A. Headache 2000, 40:300-305.
33. Amy M y col. Botulinum toxin type A therapy in chronic pain disorders. Arch Phys Med Rehab.2003. vol 84, supp 1:69-73.
34. Freund B y col. The use of botulinum toxin in the treatment of refractory Cluster headache: case report. Cephalalgia 2000, 20:329-330.
35. Robins l y col. Botulinum toxin for cluster headache. Cephalalgia 2000, 21:499-500.
36. Olesen, Lipton R. Headache Classification Update 2004. Current Opinion Neurol 2004, 17:275-282.
37. Pagina oficial de la Asociación Argentina de Cefaleas (AAC) www.cefaleas.org.ar.